Clinical trial
A Phase 3 Trial Comparing Cyclophosphamide,Bortezomib,and Dexamethasone (CyBorD) and Bortezomib,Doxorubicin,and Dexamethasone (PAD) in the Treatment of Newly Diagnosed Multiple Myeloma
NCT02362165 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Trial Comparing Cyclophosphamide,Bortezomib,and Dexamethasone (CyBorD) and Bortezomib,Doxorubicin,and Dexamethasone (PAD) in the Treatment of Newly Diagnosed Multiple Myeloma
- Lead sponsor
- Sun Yat-sen University
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- April 30, 2015
- Completion date
- May 31, 2018
- Enrollment
- 236 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.